These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 22805901)

  • 1. Effectiveness of the information technology-aided program of relapse prevention in schizophrenia (ITAREPS): a randomized, controlled, double-blind study.
    Španiel F; Hrdlička J; Novák T; Kožený J; Höschl C; Mohr P; Motlová LB
    J Psychiatr Pract; 2012 Jul; 18(4):269-80. PubMed ID: 22805901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychiatrist's adherence: a new factor in relapse prevention of schizophrenia. A randomized controlled study on relapse control through telemedicine system.
    Spaniel F; Novak T; Bankovska Motlova L; Capkova J; Slovakova A; Trancik P; Matejka M; Höschl C
    J Psychiatr Ment Health Nurs; 2015 Dec; 22(10):811-20. PubMed ID: 26176646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Information Technology Aided Relapse Prevention Programme in Schizophrenia excluding the effect of user adherence: a randomized controlled trial.
    Komatsu H; Sekine Y; Okamura N; Kanahara N; Okita K; Matsubara S; Hirata T; Komiyama T; Watanabe H; Minabe Y; Iyo M
    Schizophr Res; 2013 Oct; 150(1):240-4. PubMed ID: 23998952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ITAREPS: information technology aided relapse prevention programme in schizophrenia.
    Spaniel F; Vohlídka P; Hrdlicka J; Kozený J; Novák T; Motlová L; Cermák J; Bednarík J; Novák D; Höschl C
    Schizophr Res; 2008 Jan; 98(1-3):312-7. PubMed ID: 17920245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Schizophrenia prediction with the adaboost algorithm.
    Hrdlicka J; Klema J
    Stud Health Technol Inform; 2011; 169():574-8. PubMed ID: 21893814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.
    Csernansky JG; Mahmoud R; Brenner R;
    N Engl J Med; 2002 Jan; 346(1):16-22. PubMed ID: 11777998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder.
    Williams JM; Anthenelli RM; Morris CD; Treadow J; Thompson JR; Yunis C; George TP
    J Clin Psychiatry; 2012 May; 73(5):654-60. PubMed ID: 22697191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine.
    Bender S; Olbrich HM; Fischer W; Hornstein C; Schoene W; Falkai P; Haarmann C; Berger M; Gastpar M;
    Pharmacopsychiatry; 2003; 36(2):61-9. PubMed ID: 12734763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia.
    Barnett PG; Scott JY; Krystal JH; Rosenheck RA;
    J Clin Psychiatry; 2012 May; 73(5):696-702. PubMed ID: 22697193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.
    Kane JM; Sanchez R; Perry PP; Jin N; Johnson BR; Forbes RA; McQuade RD; Carson WH; Fleischhacker WW
    J Clin Psychiatry; 2012 May; 73(5):617-24. PubMed ID: 22697189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Information Technology Aided Relapse Prevention Programme in Schizophrenia: an extension of a mirror-design follow-up.
    Spaniel F; Vohlídka P; Kozený J; Novák T; Hrdlicka J; Motlová L; Cermák J; Höschl C
    Int J Clin Pract; 2008 Dec; 62(12):1943-6. PubMed ID: 18795967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.
    Lerner V; Miodownik C; Gibel A; Sirota P; Bush I; Elliot H; Benatov R; Ritsner MS
    J Clin Psychiatry; 2013 Dec; 74(12):1224-32. PubMed ID: 24434091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Maintenance electroconvulsive therapy and treatment of refractory schizophrenia].
    Lévy-Rueff M; Jurgens A; Lôo H; Olié JP; Amado I
    Encephale; 2008 Oct; 34(5):526-33. PubMed ID: 19068343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Education in schizophrenia: how patients and their relatives assess the relapse prevention programme PREDUKA].
    Motlová LB; Dragomirecká E; Matelová S; Otevrelová R; Cermáková R; Cermák J; Lednická E; Hegedüsová R; Hübsch T; Rothanzlová S; Tomesová M; Spaniel F; Kitzlerová E
    Cas Lek Cesk; 2010; 149(1):21-5. PubMed ID: 20662456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personal and social functioning in schizophrenia: defining a clinically meaningful measure of maintenance in relapse prevention.
    Nicholl D; Nasrallah H; Nuamah I; Akhras K; Gagnon DD; Gopal S
    Curr Med Res Opin; 2010 Jun; 26(6):1471-84. PubMed ID: 20402565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prodromal symptoms in schizophrenic relapse: A descriptive and comparative study].
    Bouhlel S; Jones Y; Khelifa E; Msolly M; Melki W; El-Hechmi Z
    Encephale; 2012 Oct; 38(5):397-403. PubMed ID: 23062453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.